Lemzoparlimab
- Generic Name
- Lemzoparlimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2377483-71-9
- Unique Ingredient Identifier
- 0H2XLR2IKW
- Background
Lemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT04912063
- Locations
- 🇮🇱
Hadassah Medical Center-Hebrew University /ID# 227275, Jerusalem, Yerushalayim, Israel
🇦🇺Austin Health /ID# 227717, Heidelberg, Victoria, Australia
🇮🇱Rabin Medical Center /ID# 227738, Petakh Tikva, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath